1. Home
  2. STTK vs BBNX Comparison

STTK vs BBNX Comparison

Compare STTK & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$4.18

Market Cap

538.3M

Sector

Health Care

ML Signal

HOLD

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$14.69

Market Cap

493.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
BBNX
Founded
2016
2015
Country
United States
United States
Employees
N/A
423
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
538.3M
493.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STTK
BBNX
Price
$4.18
$14.69
Analyst Decision
Buy
Strong Buy
Analyst Count
7
10
Target Price
$10.00
$23.80
AVG Volume (30 Days)
860.8K
780.1K
Earning Date
05-01-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
53.02
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
N/A
Revenue This Year
N/A
$34.90
Revenue Next Year
N/A
$34.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$8.80
52 Week High
$8.33
$32.71

Technical Indicators

Market Signals
Indicator
STTK
BBNX
Relative Strength Index (RSI) 28.36 71.48
Support Level $3.67 $9.34
Resistance Level $4.23 $15.53
Average True Range (ATR) 0.51 0.96
MACD -0.15 0.27
Stochastic Oscillator 27.29 91.73

Price Performance

Historical Comparison
STTK
BBNX

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Share on Social Networks: